SCHEMBL3434971

SCHEMBL3434971

[C-]#[N+]C1=C[C@]2(C)[C@H]3CC[C@@H]4[C@H]5[C@H](C(=C)C)CC[C@]5(C(=O)O)CC[C@@]4(C)[C@]3(C)CC[C@H]2C(C)(C)C1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 8/20 0.61
LMNA P02545 2/20 0.61
NT5E P21589 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
GLI1 P08151 3/20 0.56
RELA Q04206 1/20 0.56
PTPN1 P18031 2/20 0.56
USP2 O75604 1/20 0.56
HIF1A Q16665 1/20 0.56
AKR1B10 O60218 1/20 0.56
ALB P02768 1/20 0.56
POLB P06746 1/20 0.56
AKR1B1 P15121 1/20 0.56
DPP4 P27487 1/20 0.56
RORC P51449 1/20 0.56
SAE1 Q9UBE0 1/20 0.56
UBA2 Q9UBT2 1/20 0.56
MAPT P10636 1/20 0.55
ATM Q13315 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3433671 0.92 GPBAR1 (0.51) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL3434963 0.92 GPBAR1 (0.51) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL3434483 0.91 GPBAR1 (0.50) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL6119147 0.87 GPBAR1 (0.65) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL3434478 0.86 GPBAR1 (0.47) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL3434966 0.85 GPBAR1 (0.45) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL5442215 0.84 GPBAR1 (0.64) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL14398790 0.84 GPBAR1 (0.64) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL13351911 0.84 GPBAR1 (0.64) GPBAR1LMNANT5ESMN1; SMN2GLI1
SCHEMBL3525117 0.84 GPBAR1 (0.64) GPBAR1LMNANT5ESMN1; SMN2GLI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778990-B2 Betulinic acid derivatives and methods of use thereof TRUSTEES OF DARTMOUTH COLLEGE (US) 2014-07-15 US disclosed
US-20120101149-A1 Betulinic Acid Derivatives and Methods of Use Thereof REATA PHARMACEUTICALS, INC. 2012-04-26 US disclosed
US-20070232577-A1 Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin ADVANCED LIFE SCIENCES, INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232577-A1 Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin BET1, PGGT1B, BRCA1 GPBAR1 225/4885LMNA 4313/4885NT5E 3553/4885
US-20120101149-A1 Betulinic Acid Derivatives and Methods of Use Thereof BET1, PGGT1B, CYP3A5 GPBAR1 75/4885LMNA 1890/4885NT5E 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.